Navigation Links
ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
Date:11/8/2011

MOUNTAIN VIEW, Calif., Nov. 8, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology (ACR).  CCX354 is an orally-active small molecule that specifically targets and inhibits the chemokine receptor known as CCR1, which is implicated in the development and progression of rheumatoid arthritis (RA).  Results showed that CCX354 was safe and well tolerated by patients with RA in this clinical trial, and demonstrated clinical and biological activity at a dose of 200 mg once daily.  These data were highlighted today in a late-breaker oral presentation in Chicago entitled "Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase II Rheumatoid Arthritis Study".

"The initial cloning and characterization of CCR1 as well as the chemokine known as RANTES, one of the main ligands for CCR1, was accomplished by the founder of ChemoCentryx over twenty years ago," stated Paul-Peter Tak, M.D., Ph.D., Lead Investigator and Professor at AMC/University of Amsterdam, currently also Senior Vice President/Head, Therapy Area ImmunoInflammation at GlaxoSmithKline.  "Although there has been strong evidence implicating CCR1 in the pathology of RA, this is the first time that an investigational CCR1 antagonist has successfully demonstrated clinical efficacy in patients with this disease."

The results reported from this study, known as the CARAT-2 clinical trial, show that patients who met inclusion criteria at the start of dosing (Day 1 eligible) had an ACR20 response at Week 12 of 56% in patients receiving 200 mg CCX354 once daily compared to 44% in patients receiving 100 mg twice daily, and 30% in patients receiving placebo. The difference between 200 mg once daily and placebo was statistically significant (p=0.014). The decrease in CRP, a marker of inflammation, was statistically significant in the 200 mg QD group com
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
2. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
3. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
4. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
6. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
7. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Depomed, Inc. (NASDAQ: DEPO ) today ... th Annual Healthcare Conference in New York City ... is scheduled for 8:00 am EST (5:00 am PST) on Tuesday ... can be accessed via the Investor Relations page of the Depomed ... be archived for 30 days on the company,s website. ...
(Date:11/21/2014)... Nov. 20, 2014   Wellcentive , the ... for healthcare organizations, announced today being named one ... Intel Innovation Award .  Sponsored by Intel, the ... its fourth year, recognizes companies developing leading-edge technology ... delivery processes. Wellcentive,s Mason ...
(Date:11/18/2014)... LAWRENCE, Mass. , Nov. 18, 2014 /PRNewswire/ ... NXTM ), a leading manufacturer of innovative ... its new  Streamline® Express dialyzer for the ... blood tubing set, which is designed to reduce ... and to reduce the number of touch point ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3NxStage Launches New Streamline Express Dialyzer With Pre-attached Blood Tubing Set 2
(Date:11/22/2014)... In order to provide better services, LunaDress has updated its ... business knows that a suitable cocktail party dress is crucial ... the party dresses supplier’s high quality items are offered at ... in fashion industry, LunaDress understands that it is not easy ... always raises the professional level and innovation ability. The growth ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... of power morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive ... 450 new signatures since the end of October, Bernstein ... had signed the petition as of November 21st, 2014. ... 31st, when 86,042 supporters had signed on to the ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication ... The article states that, “While they give off the appearance ... go into creating this powerful look.” , One of the ... choosing which kind of block matches your home environment and ... “The two main options are concrete and stone blocks. But ...
(Date:11/22/2014)... 2014 Hastings and Hastings, a discount ... announces providing clients with the option of leaving an ... a flexible, intuitive and easy to navigate website that ... to Google + allows clients to research the Hastings ... more informed decision when retaining an attorney. Those who ...
(Date:11/22/2014)... The Sports Conflict Institute is pleased to announce ... of conflict resolution professionals. Baroff comes to SCI as an ... over 30 years experience as an arbitrator, educator, and ombuds ... connect with SCI and bring my conflict resolution skills and ... a complete sports focus,” says Baroff. , “Roy has a ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3
... a link between air pollution and heart attacks. ... and Haemostasis looks specifically at airborne particulate matter ... coal and also from forest fires, reports science ... and long-term exposure to these particulates is associated ...
... already a huge health problem in Asia that is getting ... years (by 2050), one out of every two fractures in ... figures projected above, it would be sensible for men and ... of their lifestyle. ,Osteoporosis, in which the bones ...
... a study in the September issue of Archives of ... for poor health and mental conditions//. ,Besides basic ... and understand numerical information such as that on prescription ... information such as appointment slips, to be able to ...
... face more than twice the risk of developing breast ... Netherlands examined the relation between handedness// and incidence of ... born between 1932 and 1941, reports science portal EurekAlert. ... such as social and economic status, smoking habits, family ...
... presenting a paper at the 109th Annual Meeting & ... held September 25-28, 2005 on the impact of age ... adult patients with inflammatory paranasal sinus disease at a ... disease is used to encompass CRS, CRS with polyposis, ...
... in the plant kingdom among pulses. Besides providing the body ... to have numerous other health benefits//. It is nicknamed as ... of diabetes, and improve overall health. ,Sometime back ... the Post menopausal period but now men have a reason ...
Cached Medicine News:Health News:Beauty Queens Urge On The Importance Of Maintaining Bone Integrity 2Health News:Age Can Changes Symptoms Of Sinusitis 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: